Beat AML® is transforming treatment for people with acute myeloid leukemia
Doctors diagnose over 20,000 Americans with acute myeloid leukemia (AML) each year, making it one of the most common types of leukemia — and one of the most aggressive.
In 2016, The Leukemia & Lymphoma Society (LLS) launched the Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced technology to examine the genetic make-up of each patient’s cancer and then matches patients to the most promising targeted treatment.
So far, Beat AML has:
- Improved survival for AML patients enrolled in a Beat AML study (compared to standard chemotherapy)
- Facilitated precision medicine treatment for over 400 AML patients in a Beat AML sub-study
- Sequenced AML genomes for over 1,400 patients
- Offered clinical studies to treat 15 unique types of AML
BEAT AML® MASTER CLINICAL TRIAL CHRONICLES
Coloring Outside the Lines
Coloring Outside the Lines, a new documentary from award-winning independent filmmakers and LLS, follows four cancer patients given months or less to live and chronicles their experience in the Beat AML trial.
Watch: Donna Kelley’s experience with Beat AML
Watch: Darlene Chroniger’s experience with Beat AML
What makes the Beat AML Master Clinical Trial groundbreaking?
LLS brought together a range of blood cancer experts to collaborate like never before to disrupt the status quo in AML treatment
The master clinical trial protocol allows different patients, depending on the genetic features of their AML, to enroll in Beat AML sub-studies using different treatment approaches
Advanced technology provides genomic analysis to match patients to precision treatment within seven days
Precision medicine approach moves people away from one-size-fits-all chemotherapy
Beat AML Leadership
John C. Byrd, MD
University of Cincinnati College of Medicine
Brian Druker, MD
The Knight Cancer Institute at Oregon Health & Science University
Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center in New York City
Ashley Yocum, PhD
Beat AML Master Protocol Lead, The Leukemia & Lymphoma Society
AML Facts
There are more than 10 types of AML and other rare mutations
Each type of AML responds to different therapies
Only 1 in 3 adults with AML survives five years, this drops to 1 in 6 for adults diagnosed at 60 and older
More than 11,000 Americans die of AML each year
Learn more about the LLS Beat AML Master Trial
How LLS is leading the way in AML research
- The Beat AML Master Clinical trial continues to grow by:
- Testing precision medicine for adults with AML
- Exploring ways to reduce side effects and improve patients’ quality of life
- Making clinical trials more patient friendly by using new technology to monitor vital signs, symptoms, and side effects of treatment with fewer trips to the doctor
- The Pediatric Acute Leukemia (PedAL) Master Clinical Trial matches children with AML to precision medicine therapies
- Over 25% of the research LLS funds is aimed at finding cures and improving quality of life for AML patients—that’s $60 million!
- The LLS Therapy Acceleration Program has over 20 active investments in AML therapies currently in development